PhaseBio Enters Worldwide License Agreement With MedImmune for a Reversal Agent for Ticagrelor
November 28, 2017—PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, announced that the company has entered an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for PB2452 (formerly MEDI2452), a phase 1–ready reversal agent for ticagrelor. PhaseBio advised that it plans to initiate a phase 1 study in the first half of 2018.
According to the company, ticagrelor is unique among P2Y12 antagonist antiplatelet agents because of its ability to reversibly bind to the receptor, whereas other P2Y12 antagonists bind permanently.
PB2452 is an investigational, intravenous Fab antibody fragment designed to rapidly and specifically reverse the antiplatelet effects of ticagrelor in rare emergency situations. PB2452 binds to ticagrelor and its active metabolite AR-C124910XX. In preclinical studies, PB2452 demonstrated high affinity and specific binding to ticagrelor and was shown to reverse ticagrelor-mediated inhibition of platelet aggregation and normalize bleeding.
In the company's announcement, Cam Patterson, MD, commented, “PB2452 has the potential to reverse the antiplatelet effects of ticagrelor in rare emergency situations, while also reducing the current waiting period required ahead of emergency surgeries for patients on antiplatelet therapy.” Dr. Patterson, a cardiologist, is Senior Vice President and Chief Operating Officer of New York-Presbyterian/Weill Cornell Medical Center in New York, New York.